Asian Pacific Journal of Cancer Prevention

  • 제14권9호
  • /
  • Pages.5489-5494
  • /
  • 2013
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Prevelance of Common YMDD Motif Mutations in Long Term Treated Chronic HBV Infections in a Turkish Population

  • Alagozlu, Hakan (Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University) ;
  • Ozdemir, Ozturk (Department of Medical Genetics, Faculty of Medicine, Canakkale Onsekiz Mart University) ;
  • Koksal, Binnur (Department of Medical Genetics, Faculty of Medicine, Cumhuriyet University) ;
  • Yilmaz, Abdulkerim (Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University) ;
  • Coskun, Mahmut (Department of Medical Biology, Faculty of Medicine, Canakkale Onsekiz Mart University)
  • 발행 : 2013.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In the current study we aimed to show the common YMDD motif mutations in viral polymerase gene in chronic hepatitis B patients during lamivudine and adefovir therapy. Forty-one serum samples obtained from chronic hepatitis B patients (24 male, 17 female; age range: 34-68 years) were included in the study. HBV-DNA was extracted from the peripheral blood of the patients using an extraction kit (Invisorb, Instant Spin DNA/RNA Virus Mini Kit, Germany). A line probe assay and direct sequencing analyses (INNO-LIPA HBV DR v2; INNOGENETICS N.V, Ghent, Belgium) were applied to determine target mutations of the viral polymerase gene in positive HBV-DNA samples. A total of 41 mutations located in 21 different codons were detected in the current results. In 17 (41.5%) patients various point mutations were detected leading to lamivudin, adefovir and/or combined drug resistance. Wild polymerase gene profiles were detected in 24 (58.5%) HBV positive patients of the current cohort. Eight of the 17 samples (19.5%) having rtM204V/I/A missense transition and/or transversion point mutations and resistance to lamivudin. Six of the the mutated samples (14.6%) having rtL180M missense transversion mutation and resistance to combined adefovir and lamivudin. Three of the mutated samples (7.5%) having rtG215H by the double base substituation and resistance to adefovir. Three of the mutated samples (7.5%) having codon rtL181W due to the missense transversion point mutations and showed resistance to combined adefovir and lamivudin. Unreported novel point mutations were detected in the different codons of polymerase gene region in the current HBV positive cohort fromTurkish population. The current results provide evidence that rtL180M and rtM204V/I/A mutations of HBV-DNA may be associated with a poor antiviral response and HBV chronicity during conventional therapy in Turkish patients.

키워드

참고문헌

  1. Agca H, Sayiner AA, Sengonul A et al., (2011). A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations. Mikrobiyol Bul, 45, 664-76.
  2. Allen MI, Deslauriers M, Andrews CW, et al (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 27, 1670-7. https://doi.org/10.1002/hep.510270628
  3. Angus P, Vaughan R, Xiong S, et al (2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, 292-7. https://doi.org/10.1016/S0016-5085(03)00939-9
  4. Aspinall EJ, Hawkins G, Fraser A, et al (2011). Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond), 61, 531-40. https://doi.org/10.1093/occmed/kqr136
  5. Balzarini J, Wedgwood O, Kruining J, et al (1996). Anti-HIV and anti-HBV activity and resistance profile of 3TC and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 2, 363-9.
  6. Bartholomeusz A, Locarnini SA (2006). Antiviral drug resistance: clinical consequences consequences and molecular aspects. Semin Liver Dis, 26, 162-70. https://doi.org/10.1055/s-2006-939758
  7. Baumert TF, Rogers SA, Hasegawa K, Liang TJ (1996). Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest, 98, 2268-76. https://doi.org/10.1172/JCI119037
  8. Carman WF, Trautwein C, van Deursen FJ, et al (1996). Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology, 24, 489. https://doi.org/10.1002/hep.510240304
  9. Chen Y, Wang L, Xu H, et al (2013). Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis. Oncol Rep, 30, 1906-12. https://doi.org/10.3892/or.2013.2652
  10. Chen YM, Wu SH, Qiu CN, et al (2013). Hepatitis B virus subgenotype C2- and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively. Braz J Med Biol Res, 46, 614-22. https://doi.org/10.1590/1414-431X20133032
  11. Fontana RJ, Keeffe EB, Carey W, et al (2002). Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl, 8, 433-9. https://doi.org/10.1053/jlts.2002.32983
  12. Fung SK, Chae HB, Fontana RJ, et al (2006). Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol, 44, 283-90 https://doi.org/10.1016/j.jhep.2005.10.018
  13. Gaillard RK, Barnard J, Lopez V, et al (2002). Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother, 46, 1005-13. https://doi.org/10.1128/AAC.46.4.1005-1013.2002
  14. Ganem D, Prince AM (2004). Hepatitis B virus infection− natural history and clinical consequences. N Engl J Med, 350, 1118-29. https://doi.org/10.1056/NEJMra031087
  15. Gao C, Fang L, Zhao HC, et al (2013). Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int, 12, 385-93. https://doi.org/10.1016/S1499-3872(13)60060-0
  16. Geramizadeh B, Nikeghbalian S, Kazemi K, et al (2013). Hepatocellular carcinoma in explanted livers of patients with genotype d HBV cirrhosis: report of the first experience from Iran. Arch Iran Med, 16, 348-50.
  17. Guerrieri F, Belloni L, Pediconi N, Levrero M (2013). Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis, 33, 147-56. https://doi.org/10.1055/s-0033-1345721
  18. Gwak GY, Lee CY, Lee DH, et al (2011). Clinical impact of the development of YMDD mutants in hepatitis B virusassociated glomerulonephritis. Hepatogastroenterology, 58, 1291-5. https://doi.org/10.5754/hge07389
  19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al (2006). Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology, 131, 1743-51. https://doi.org/10.1053/j.gastro.2006.09.020
  20. Johnson MS, McClure MA, Feng DF, et al (1986). Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci USA, 83, 7648-52. https://doi.org/10.1073/pnas.83.20.7648
  21. Kim HJ, Park JH, Park DI, et al (2012). The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment. Liver Int, 32, 303-10. https://doi.org/10.1111/j.1478-3231.2011.02647.x
  22. Kohlstaedt LA, Wang J, Friedman JM, et al (1992). Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-90. https://doi.org/10.1126/science.1377403
  23. Lai CL, Chien RN, Leung NW, et al (1998). A one year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med, 339, 61-8. https://doi.org/10.1056/NEJM199807093390201
  24. Lavarone M, Colombo M (2013). HBV infection and hepatocellular carcinoma. Clin Liver Dis, 17, 375-97. https://doi.org/10.1016/j.cld.2013.05.002
  25. Lee CZ, Lee HS, Huang GT, et al (2006). Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol, 12, 5301-5. https://doi.org/10.3748/wjg.v12.i33.5301
  26. Lee SH, Kim HS, Byun IS, et al (2012). Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol, 84, 217-22. https://doi.org/10.1002/jmv.23191
  27. Lee YS, Suh DJ, Lim YS, et al (2006). Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43, 1385-91. https://doi.org/10.1002/hep.21189
  28. Li D, Cheng H, Gong W, et al (2013). Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization. J Virol Methods, 187, 259-63. https://doi.org/10.1016/j.jviromet.2012.11.017
  29. Lin CL, Kao JH (2008). Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci, 15, 137-45. https://doi.org/10.1007/s11373-007-9225-8
  30. Liu K, Hou W, Zumbika E, Ni Q (2005). Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Science B, 6, 1182-8. https://doi.org/10.1631/jzus.2005.B1182
  31. Markowitz JS, Martin P, Conrad AJ, et al (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatolog, 28, 585-9. https://doi.org/10.1002/hep.510280241
  32. Matsuda M, Suzuki F, Suzuki Y, et al (2004). YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol, 74, 361-6. https://doi.org/10.1002/jmv.20185
  33. Mello FC, Lago BV, Lewis-Ximenez LL, et al (2012). Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol, 12, 96. https://doi.org/10.1186/1471-2180-12-96
  34. Ogata N, Fujii K, Takigawa S, et al (1999). Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol, 59, 270-6. https://doi.org/10.1002/(SICI)1096-9071(199911)59:3<270::AID-JMV2>3.0.CO;2-1
  35. Poch O, Sauvaget I, Delarue M, Tordo N (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J, 8, 3867-74.
  36. Sarma MP, Asim M, Medhi S, et al (2012). Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Biol Med, 9, 172-81.
  37. Sato S, Suzuki K, Akahane Y, et al (1995). Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med, 122, 241-8. https://doi.org/10.7326/0003-4819-122-4-199502150-00001
  38. Schildgen O, Sirma H, Funk A, et al (2006). Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 354, 1807-12. https://doi.org/10.1056/NEJMoa051214
  39. Schildgen V, Ziegler S, Tillmann RL, Schildgen O (2010). Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J, 7, 167. https://doi.org/10.1186/1743-422X-7-167
  40. Singh S, Singh PP, Roberts LR, Sanchez W (2013). Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, [Epub ahead of print].
  41. Tan YW, Ge GH, Zhao W, et al (2012). YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis, 16, 250-5. https://doi.org/10.1016/S1413-8670(12)70319-7
  42. Vassiliadis T, Nikolaidis N, Giouleme O, et al (2005). Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther, 21, 531-7. https://doi.org/10.1111/j.1365-2036.2005.02388.x
  43. Villamil FG (2002). Hepatitis B progress in the last 15 years. Liver Transpl, 8, 59-66. https://doi.org/10.1053/jlts.2002.35782
  44. Wang LL, Yu XJ, Dong QJ, et al (2012). HBV genotypes distribution and YMDD spontaneous mutation in Qingdao population. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 26, 250-2.
  45. Wu F, Wu MJ, Zhuge XL et al (2012). Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int, 11, 172-6. https://doi.org/10.1016/S1499-3872(12)60144-1
  46. Yang JH, Zhang H, Chen XB, et al (2013). Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol, 19, 3861-5. https://doi.org/10.3748/wjg.v19.i24.3861
  47. Zhao J, Guo Y, Yan Z, et al (2012). The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis, 44, 44-7. https://doi.org/10.3109/00365548.2011.598871

피인용 문헌

  1. Expression and Clinical Significance of Myeloid Derived Suppressor Cells in Chronic Hepatitis B Patients vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4367
  2. Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1411
  3. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis vol.38, pp.5, 2016, https://doi.org/10.1007/s11096-016-0358-6